

The **AlphaCentric LifeSci Healthcare Fund** leverages the significant scientific and investment success of portfolio manager, Mark Charest, PhD, and sub-adviser LifeSci Partners, a global biotech/healthcare advisory firm, sourcing investments in breakthrough health and life science companies.

Why Invest?

- Unconstrained Biotech/Healthcare Portfolio designed to outperform broad market exposure by focusing on the following areas:
 - Disruptive life sciences innovators
 - Robust cash flow/revenue growth companies
 - Direct funding through private placements, IPOs & other structured transactions
- Portfolio Manager is co-inventor of FDA approved therapeutic & eight drug patents
- Concentrated exposure not found in the S&P 500
- Offers ability to capture upside while defending against drawdowns

Fund Performance as of 12/31/21 (Annualized if greater than 1 year)

Inception Date: 11/29/19	QTD	6 Months	YTD	1 Year	2 Year	Inception
LYFIX	-4.84	-8.49	-3.35	-3.35	22.31	21.98
LYFAX	-4.92	-8.63	-3.61	-3.61	22.00	21.74
LYFCX	-5.07	-8.97	-4.32	-4.32	21.51	21.27
S&P Biotechnology Select Industry TR Index	-10.95	-17.36	-20.38	-20.38	8.59	9.15
S&P 500 Health Care Sector TR Index	11.17	12.77	26.13	26.13	19.62	20.75
Class A After Sales Charges	-10.41	-13.87	-9.14	-9.14	18.43	18.33

Past performance is no guarantee of future results. There is no assurance that the Fund will achieve its investment objective.

The maximum sales charge for Class "A" Shares is 5.75%. Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. To obtain the most recent month end performance information or the funds prospectus please call the Fund, toll free at 1-844-ACFUNDS (844-223-8637). You can also obtain a prospectus at www.AlphaCentricFunds.com.

All data is as of the most recent quarter-end other than the annual return which is annualized.

Performance & Risk Statistics as of 12/31/21

	Cumulative Return	Annualized Return	Standard Deviation	Sharpe Ratio (RF 0.0444%)	Risk-Free Rate	Alpha	Beta	R-Squared
LYFIX	51.39%	22.02%	19.79%	1.11	0.0444%	17.08%	0.54	0.63
S&P Biotechnology Select Industry TR Index	20.05%	9.17%	28.00%	0.33	-	-	-	-
S&P 500 Health Care Sector TR Index	48.23%	20.79%	16.14%	1.29	-	-	-	-

The **S&P Biotechnology Select Industry Total Return Index** represents the bio-technology sub-industry portion of the S&P Total Markets Index.

The **S&P 500 Health Care Sector TR Index** comprises those companies included in the S&P 500 that are classified as members of the GICS health care sector.

There is no assurance that the Fund will achieve its investment objective. You cannot invest directly in an index. Unmanaged index returns do not reflect fees, expenses or sales charges.

Sharpe Ratio: A risk-adjusted measure of a fund's performance that indicates a fund's return per unit of risk, defining risk as volatility (standard deviation). **Risk-adjusted Alpha:** A measure of the difference between a fund's actual returns and its expected performance, given its level of risk as measured by beta. **Beta:** A measure of a fund's sensitivity to market movements. **R-squared:** A measure of the relationship between a portfolio and its benchmark.

Fund Objective

The Fund's objective is to achieve long-term capital appreciation.

Investment Strategy

- The Fund seeks to achieve its investment objective by leveraging the research performed by Mark Charest, PhD and the scientists, researchers, and medical doctors at LifeSci Partners
- The Fund invests in small, mid, and large cap biotech, pharmaceutical, healthcare and life science companies addressing areas of high unmet medical need
- Fundamental bottom-up research is performed on a broad, primarily US, watch list of roughly 200 companies
- The combination of LifeSci's medical and scientific research, coupled with their investment experience, provides investors a differentiated perspective

How to Invest

Share Class	Ticker	CUSIP
Class A	LYFAX	62827P352
Class C	LYFCX	62827P345
Class I	LYFIX	62827P337

Min. Initial Investment: \$2,500

Min. Subsequent Investment: \$100

There is no assurance that the Fund will achieve its investment objective. You cannot invest directly in an index and unmanaged index returns do not reflect any fees, expenses or sales charges.

Fund Management

Investment Advisor
AlphaCentric Advisors, LLC

Investment Sub-Advisor
LifeSci Fund Management

Portfolio Manager

Mark Charest, PhD

- 12+ year career as an investor at several specialized \$1B+ AUM healthcare funds
- Led Medicinal Chemistry Lab at the Novartis Institutes for BioMedical Research focused on Oncology drug discovery
- Inventor on 8 drug patents
- Portfolio Manager at New Leaf Venture Partners
- National Science Foundation Graduate Research Fellow
- PhD and MS in Chemistry and Chemical Biology from Harvard University

Share Class Information

Share Class	Net Expense*	Gross Expense
Class A LYFAX	1.65%	2.77%
Class C LYFCX	2.40%	3.52%
Class I LYFIX	1.40%	2.52%

Inception date: 11/29/19

*The advisor has contractually agreed to waive fees and/or reimburse expenses to maintain the Fund's total annual operating expense ratio at 1.65%, 2.40% and 1.40% for Class A shares, Class C shares and Class I shares, respectively, excluding 12b-1 fees through July 31, 2022.

Investors should carefully consider the investment objectives, risks, charges and expenses of the AlphaCentric Funds. This and other important information about the Fund is contained in the prospectus, which can be obtained by calling 844-ACFUNDS (844-223-8637) or at www.AlphaCentricFunds.com. The prospectus should be read carefully before investing.

The AlphaCentric Funds are distributed by Northern Lights Distributors, LLC, member FINRA/SIPC. AlphaCentric Advisors, LLC is not affiliated with Northern Lights Distributors, LLC.

1048-NLD-01112022

Contact Us

- +1 855 674 FUND
- www.alphacentricfunds.com
- info@alphacentricfunds.com

Investment Process

- 1 Perform systematic screening of corporate universe (500+ companies with >\$1 Trillion aggregate market cap) using proprietary fundamental scientific and financial analysis to identify watch list of potential investments
- 2 Perform sector diligence and gather Key Opinion Leader input via LifeSci network to identify highly innovative thematic areas of interest and robust growth opportunities; monitor profitable company financial metrics and ratios using proprietary analytics dashboard to identify potential dislocations
- 3 Identify targets and perform comprehensive fundamental analysis using proprietary diligence methodology covering a broad range of factors, including scientific/medical evidence underlying key products, competitive landscape, regulatory strategy, market size, management team background, and analyst coverage and projections
- 4 Construct portfolio using thesis driven price targets for entry and exit. Relative risk/reward analysis guides position size and sub sector exposures:
 - Conduct ongoing contact with management teams and Key Opinion Leader community to validate ideas
 - Monitor price changes relative to fundamental sector changes and scientific/medical data outputs

Top Ten Holdings as of 12/31/21

Holding	% of Portfolio
Galapagos NV	4.86%
Arena Pharmaceuticals Inc	4.36%
Incyte Corp	4.17%
MorphoSys AG	3.89%
Zogenix Inc	3.81%
Jazz Pharmaceuticals PLC	3.62%
Puma Biotechnology Inc	3.46%
ACADIA Pharmaceuticals Inc	3.42%
Collegium Pharmaceutical Inc	3.21%
Arcutis Biotherapeutics Inc	3.09%

Holdings are subject to change and should not be considered investment advice.

Important Risk Information

Investing in the Fund carries certain risks. The Fund will invest a percentage of its assets in derivatives, such as futures and options contracts. The use of such derivatives and the resulting high portfolio turn-over may expose the Fund to additional risks that it would not be subject to if it invested directly in the securities and commodities underlying those derivatives. The Fund may experience losses that exceed those experienced by funds that do not use futures contracts and options strategies. Investing in commodities markets may subject the Fund to greater volatility than investments in traditional securities. Currency trading risks include market risk, credit risk and country risk. Foreign investing involves risks not typically associated with U.S. investments. Changes in interest rates and the liquidity of certain investments could affect the Fund's overall performance. The Fund is non-diversified and as a result, changes in the value of a single security may have significant effect on the Fund's value.

Other risks include U.S. Government securities risks and investments in fixed income securities. Typically, a rise in interest rates causes a decline in the value of fixed income securities or derivatives owned by the Fund. Furthermore, the use of leveraging can magnify the potential for gain or loss and amplify the effects of market volatility on the Fund's share price. The Fund is subject to regulatory change and tax risks; changes to current rules could increase costs associated with an investment in the Fund. These factors may affect the value of your investment.